No Easy Way to Try New Contact Lens Brands Without a New Fitting

A contact lens prescription is brand-specific. It does not simply say '-3.00 in both eyes' — it specifies the exact manufacturer, product line, base curve, and diameter. If you wear Acuvue Oasys and want to try Dailies Total1, you cannot simply buy them: you need a new fitting appointment, a new trial period, and a new prescription. This means another office visit, another fitting fee ($85-$150+), and another round of waiting for the doctor to evaluate the lens on your eye. So what? In every other consumer product category, switching brands is trivial. If you do not like Colgate, you buy Crest. But contact lenses lock you into a specific product, and the switching cost is not just monetary — it requires scheduling an appointment, taking time off work, and potentially multiple follow-up visits. This brand lock-in suppresses competition: wearers stick with whatever their doctor first prescribed, even if a better or cheaper alternative exists, because the hassle of switching is too high. Manufacturers exploit this by raising prices on established products, knowing that switching costs create artificial loyalty. The brand-specificity of prescriptions also means that wearers cannot benefit from generic competition. Unlike pharmaceuticals, where generic equivalents exist and pharmacists can substitute, there is no concept of a 'generic contact lens.' Even lenses with identical material composition, water content, and dimensions from different manufacturers require separate prescriptions. A CooperVision MyDay and an Alcon Dailies Total1 may have similar silicone hydrogel material, but they are prescribed and purchased as entirely distinct products. Why does this persist? The clinical justification is that different lens brands have different edge designs, surface treatments, and material properties that affect fit and comfort on individual eyes. A lens that fits well on one patient may not fit another. This is true, but it is also true that for the majority of wearers with standard corneas, most major-brand daily lenses in the same category would work acceptably. The structural issue is that brand-specific prescriptions benefit both manufacturers (who enjoy reduced competition and switching costs) and prescribers (who earn fitting fees for each brand change). Manufacturers also pay optometrists to prescribe their specific brands through rebate programs, sample programs, and 'preferred provider' arrangements. The system is designed to maximize friction around brand switching, which protects margins for manufacturers and revenue for prescribers at the direct expense of consumer choice and price competition.